SCHEMBL7077375

SCHEMBL7077375

Cc1cccc(-c2cccc(S(=O)(=O)Cl)c2N)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.41
MAP4K4 O95819 1/20 0.41
ABL1 P00519 1/20 0.41
NTRK1 P04629 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
CSF1R P07333 1/20 0.41
MET P08581 1/20 0.41
PDGFRB P09619 1/20 0.41
PIM1 P11309 1/20 0.41
FGFR1 P11362 1/20 0.41
PDGFRA P16234 1/20 0.41
PRKACA P17612 1/20 0.41
LTK P29376 1/20 0.41
GRK5 P34947 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41
MAPK8 P45983 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CDK8 P49336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5679414 0.85 NPC1 (0.44) CHEK1MAP4K4ABL1NTRK1LCK
SCHEMBL8661956 0.84 SLC9A1 (0.42) CHEK1MAP4K4ABL1NTRK1LCK
SCHEMBL8592093 0.82 ALDH1A1 (0.42) MAP4K4CSF1RFGFR1PDGFRALTK
SCHEMBL7366744 0.78 L3MBTL1 (0.41) RAB9ANPC1ALDH1A1KMT2ACA1
SCHEMBL19475077 0.76 ALOX5AP (0.46) CHEK1MAP4K4ABL1NTRK1LCK
SCHEMBL30434443 0.74 MAP4K4 (0.49) CHEK1MAP4K4ABL1NTRK1LCK
SCHEMBL28399042 0.74 ADORA1 (0.53) CHEK1MAP4K4ABL1NTRK1LCK
SCHEMBL29414648 0.74 MAP4K4 (0.49) CHEK1MAP4K4ABL1NTRK1LCK
SCHEMBL28465298 0.74 MAP4K4 (0.49) CHEK1MAP4K4ABL1NTRK1LCK
SCHEMBL28072499 0.74 MAP4K4 (0.49) CHEK1MAP4K4ABL1NTRK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207920-A1 N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants SANOFI-AVENTIS (FR) 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207920-A1 N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants PROC, VKORC1, SERPINC1 CHEK1 1760/4885MAP4K4 2195/4885ABL1 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.